Itraconazole and domperidone: A placebo-controlled drug interaction study

European Journal of Clinical Pharmacology

Volumn 68, Issue 9, 2012, Pages 1287-1294

  Yoshizato, Tsuneaki ^a   Kotegawa, Tsutomu ^a   Imai, Hiromitsu ^a   Tsutsumi, Kimiko ^a   Imanaga, Junko ^a   Ohyama, Tetsuji ^a   Ohashi, Kyoichi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

CYP3A; Domperidone; Itraconazole; MDR1; Prolactin

Indexed keywords

DOMPERIDONE; ITRACONAZOLE; NAUZELIN; PLACEBO; PROLACTIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; HYSTERESIS; MALE; MAXIMUM PLASMA CONCENTRATION; MOOD; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AFFECT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; BRAIN; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOMPERIDONE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; ENZYME INHIBITORS; HALF-LIFE; HUMANS; ITRACONAZOLE; JAPAN; LINEAR MODELS; MALE; MEMBRANE TRANSPORT MODULATORS; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; PROLACTIN; SELF REPORT; UP-REGULATION; YOUNG ADULT;

EID: 84866605861     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1258-x     Document Type: Article

References (36)

1. Reddymasu SC, Soykan I, McCallum RW (2007) Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 102:2036-2045
2. Masaoka T, Tack J (2009) Gastroparesis: current concepts and management. Gut Liver 3:166-173
3. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H (1981) On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 6:61-70
4. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z (2004) Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 58:277-287
5. El Ela AA, Härtter S, Schmitt U et al (2004) Identification of Pglycoprotein substrates and inhibitors among psychoactive compounds- implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56:967-975
6. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) Pglycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524
7. Dan Y, Murakami H, Koyabu N, Ohtani H, Sawada Y (2002) Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil. J Pharm Pharmacol 54:729-733
8. Patterson D, Abell T, Rothstein R, Koch K, Barnett J (1999) A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 94:1230-1234
9. Tsujikawa K, Dan Y, Nogawa K, Sato H, Yamada Y, Murakami H, Ohtani H, Sawada Y, Iga T (2003) Potentiation of domperidoneinduced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharm Drug Dispos 24:105-114
10. Wang E-J, Lew K, Casciano CN, Clement RP, Johnson WW (2002) Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 46:160-165
11. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF (2000) Characterization of the major metabolites of verapamil as substrates and inhibitors of Pglycoprotein. J Pharmacol Exp Ther 293:376-382
12. Hughes J, Crowe A (2010) Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 113:315-324
13. Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58
14. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607
15. Shon J-H, Yoon Y-R, Hong W-S, Nguyen P-M, Lee S-S, Choi Y-G, Cha I-J, Shin J-G (2005) Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 78:191-201
16. Ohtani Y, Kotegawa T, Tsutsumi K, Morimoto T, Hirose Y, Nakano S (2002) Effect of fluconazole on the pharmacokinetics and pharmacodynamics of oral and rectal bromazepam: an application of electroencephalography as the pharmacodynamic method. J Clin Pharmacol 42:183-191
17. Inada T, Beasley CM, Tanaka Y, Walker DJ (2003) Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 18:39-48
18. Imanaga J, Kotegawa T, Imai H, Tsutsumi K, Yoshizato T, Ohyama T, Shirasaka Y, Tamai I, Tateishi T, Kyoichi O (2011) The effects of the SLCO2B1 c.1457CT polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics 21:84-93
19. Holford NH, Sheiner LB (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429-453
20. Greenblatt DJ, Harmatz JS (1993) Kinetic-dynamic modeling in clinical psychopharmacology. J Clin Psychopharmacol 13:231-234
21. Damkier P, Hansen LL, Brosen K (1999) Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 48:829-838
22. Faassen F, Vogel G, Spanings H, Vromans H (2003) Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm 263:113-122
23. Jalava KM, Partanen J, Neuvonen PJ (1997) Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609-613
24. Brouwers JRBJ, Assies J, Wiersinga WM, Huizingn G, Tytgat GN (1980) Plasma prolactin levels after acute and subchronic oral administration of domperidone and of metoclopramide: a crossover study in healthy volunteers. Clin Endocrinol 12:435-440
25. Nerozzi D, Magnani A, Sforza V, Scaramucci E, Cerilli M, Moretti C, Frajese G, Antonozzi I, Meltzer HY (1990) Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness. Psychiatry Res 34:139-147
26. Schwartz JB, Verotta D, Sheiner LB (1989) Pharmacodynamic modeling of verapamil effects under steady-state and nonsteadystate conditions. J Pharmacol Exp Ther 251:1032-1038
27. Meredith PA, Kelman AW, Elliott HL, Reid JL (1983) Pharmacokinetic and pharmacodynamic modeling of trimazosin and its major metabolite. J Pharmacokinet Biopharm 11:323-335
28. Nashan D, Knuth UA, Weidinger G, Nieschlag E (1989) The antimycotic drug terbinafine in contrast to ketoconazole lacks acute effects on the pituitary-testicular function of healthy men: a placebo-controlled double-blind trial. Acta Endocrinol 120:677-681
29. Bateman DN, Kahn C, Mashiter K, Davies DS (1978) Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. Br J Clin Pharmacol 6:401-407
30. Coppola R, Herrmann WM (1987) Psychotropic drug profiles: comparisons by topographic maps of absolute power. Neuropsychobiology 18:97-104
31. Lee DY, Lee KU, Kwon JS, Jang IJ, Cho MJ, Shin SG, Woo JI (1999) Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers. Psychopharmacology 144:272-278
32. Hesselink DA, van Schaik RH, van der Heiden IP, van derWerf M, Gregoor PJ, Lindemans J,Weimar W, van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254
33. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I (2007) CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 81:228-234
34. Micaud V, Simard C, Turgeon J (2010) Characterization of CYP3A isozymes involves in the metabolism of domperidone: role of cytochrome b(5) and inhibition by ketoconazole. Drug Metab Lett 4:95-103
35. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 82:410-426
36. Fromm MF, Schwilden H, Bachmakov I, Köning J, Bremer F, Schüttler J (2007) Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation. Eur J Clin Pharmacol 63:1129-1133